- New improvements designed to simplify NGS workflows
- Enhances crucial variant identification by means of improved applied sciences
- Roadmap advances present flexibility throughout focused and complete genome functions
BOULDER, Colo.–(BUSINESS WIRE)–#Biomarker–For greater than three a long time, Integrated DNA Technologies (IDT) has helped energy the genomics revolution, enabling scientists to decode biology with rising precision and pace. Today, as most cancers analysis enters a brand new period outlined by extremely‑delicate identification and quickly increasing biomarker landscapes, IDT is saying a collection of subsequent technology sequencing (NGS) improvements that intention to sort out longstanding bottlenecks in library preparation, focused enrichment, and complete genome evaluation.
Drawing on IDT’s long-established strengths in enzyme engineering, high-throughput oligo synthesis platform, and workflow optimization, IDT is extending its confirmed applied sciences with novel approaches tailor-made particularly to the evolving wants of most cancers researchers.
The newly introduced portfolio—which incorporates the DNA EZ v2 Library Preparation Kit, the xGen™ Exome v2 Hyb Spike-In Panel, an expanded set of 1,536 Full-Length Unique Dual Index (UDI) Adapters, and the enhanced complete genome sequencing (eWGS) system—offers a cohesive and versatile answer designed to simplify NGS workflows, sharpen crucial variant identification, and assist broad biomarker discovery throughout focused and complete genome functions.
Advancing high-precision library preparation and identification of variants
IDT’s NGS roadmap displays a multi‑omics technique constructed on differentiated chemistries and algorithms that assist DNA, methylation, and RNA sequencing workflows. Powered by IDT’s synthesis platform and enzyme engineering experience, the portfolio advances numerous biomarker modalities important for translational oncology analysis.
A key spotlight is IDT’s superior fragmentation module, engineered to cut back GC‑associated bias and decrease fragmentation‑induced artifacts—two lengthy‑standing challenges in library building. This tunable fragmentation functionality helps seamless transitions between complete genome and focused sequencing, enabling researchers to unify workflows throughout tumor‑knowledgeable profiling and minimal residual illness (MRD) functions.
Expanded exome protection to future‑proof variant interpretation
The Exome v2 Hyb Spike-In Panel introduces broadened and modernized genomic protection aligned with main databases to strengthen pathogenic variant classification and mitigate the threat of misinterpretation as requirements evolve. Designed to combine effortlessly into IDT’s present hybrid seize ecosystem, and Exome Hyb Panel v2, the panel enhances precision oncology analysis initiatives whereas preserving established workflow efficiency.
Enhanced complete genome sequencing evaluation for complete most cancers profiling
The streamlined eWGS system delivers full‑genome breadth paired with enriched protection of related genomic areas of curiosity—all inside a single, streamlined assay. This patented methodology helps excessive‑confidence identification of germline and somatic variants, structural variations, and genomic instability markers, offering researchers with extra sturdy and adaptable knowledge for complete biomarker discovery.
Commitment to integration, scalability, and future‑prepared oncology options
Together, these improvements underscore IDT’s dedication to shaping the subsequent frontier of oncology analysis with built-in, scalable, and future‑prepared sequencing options.
“These transformative updates to IDT’s NGS innovation roadmap will deliver greater precision, higher throughput, and adaptable workflows for translational and clinical research applications,” mentioned IDT President Ajay Gannerkote. “These purpose-built innovations are made possible by IDT’s specialized, high-throughput production, and history of sustained innovation, and we’re excited to be at the forefront of enabling the science that underpins the future of cancer research.”
For extra info on IDT’s NGS portfolio and capabilities, go to www.idtdna.com/NGS.
Learn extra about IDT’s bronze sponsor speak, poster displays, featured merchandise, and join with IDT at AGBT 2026 at www.idtdna.com/AGBT.
About IDT
Building from a powerful basis of innovation, experience, and reliability, Integrated DNA Technologies (IDT) has advanced from an oligo producer to a number one genomics supplier. We work shoulder-to-shoulder with scientific and international well being companions to allow genomics breakthroughs at scale. Our imaginative and prescient of enabling researchers to quickly transfer from the lab to life-changing advances displays our ongoing dedication to a more healthy, brighter future for all.
IDT is proud to be half of Danaher, a worldwide science and know-how chief. Visit www.Danaher.com to study extra about Danaher, a number one life sciences and diagnostics innovator dedicated to accelerating the energy of science and know-how to enhance human well being.
For extra details about IDT, go to www.idtdna.com and comply with the firm on LinkedIn, X, YouTube, Instagram and Bluesky.
Disclaimer: RUO — For analysis use solely. Not to be used in diagnostic procedures. Unless in any other case agreed to in writing, IDT doesn’t intend these merchandise to be utilized in scientific functions and doesn’t warrant their health or suitability for any scientific diagnostic use. Purchaser is solely answerable for all choices concerning the use of these merchandise and any related regulatory or authorized obligations.
Contacts
Media Contact: Integrated DNA Technologies
Kristina Sarenas
[email protected]
800-328-2661 (USA & Canada)
+1 319-626-8400 (exterior USA)